A clinical study on the combination of concurrent chemoradiotherapy and thalidomide for treatment of advanced esophageal cancer

Chinese Journal of Clinical Oncology

Volumn 37, Issue 15, 2010, Pages 882-886

  She, Mingjin ^a   Mar, Zusheng ^a   Li, Guizhi ^a   Wang, Qin ^a   Shen, Yongli ^a  

^a Chinese People's Armed Police Forces   (China)

Author keywords

Concurrent chemoradiotherapy; Esophageal neoplasm; Thalidomide

Indexed keywords

CISPLATIN; FLUOROURACIL; THALIDOMIDE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; ESOPHAGUS CANCER; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT OUTCOME;

EID: 77956142384     PISSN: 16727118     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1000-8179.2010.15.011     Document Type: Article

References (22)

1. Veuillez V, Rougier P, Seitz JF. Multimodal treatment of oesophageal cancer[J]. Best Pract Res Clin Gastroenterol, 2007, 21(6): 947-963.
2. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer long-term follow-up of a prospective randomized trial (RTOG 85-01)[J]. JAMA, 1999, 281(17): 1623-1627.
3. Kimura H, Kato H, Tanaka N, et al. Preoperative serum vascular endothelial growth factor-C (VEGF-C) levels predict recurrence in patients with esophageal cancer[J]. Anticancer Res, 2008, 28(1A): 165-169.
4. Neuner G, Patel A, Suntharalingam M. Chemoradiotherapy for esophageal cancer[J]. Gastrointest Cancer Res, 2009, 3(2): 57-65.
5. Nishimaki T, Shimoji H, Sunagawa H. Recent changes and future roles of esophageal cancer surgery[J]. Ann Thorac Cardiovasc Surg, 2004, 10(6): 324-332.
6. Cho SH, Shim HJ, Lee SR, et al. Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer[J]. Dis Esophagus, 2008, 21(8): 697-703.
7. Ogata Y, Fujita H, Yamana H, et al. Expression of vascular endothelial growth factor as a prognostic factor in node-positive squamous cell carcinoma in the thoracic esophagus: long-term follow-up study[J]. World J Surg, 2003, 27(5): 584-589.
8. Syrigos. KN, Zalonis A, Kotteas E, et al. Targeted therapy for oesophageal cancer: an overview[J]. Cancer Metastasis Rev, 2008, 27(2): 273-288.
9. Ansiaux R, Baudelet C, Jordan BF, et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment[J]. Clin Cancer Res, 2005, 11(2 Pt 1): 743-750.
10. Kotoh T, Dhar DK, Masunaga R, et al. Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice[J]. Surgery, 1999, 125(5): 536-544.
11. Merin JM, Lee FC. Palliative benefit for salvage treatment with capecitabine and thalidomide for gastric and/or esophageal adenocarcinoma: a retrospective case series[J]. Proc Am Soc Clin Oncol, 2002, 21: abstr 2391.
12. Kato H, Fukuchi M, Manda R, et al. Efficacy and toxicity of nedaplatin and 5-FU with radiation treatment for advanced esophageal carcinomas[J]. Anticancer Res, 2003, 23(4): 3493-3498.
13. Khan ZH, Simpson EJ, Cole AT, et al. Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass[J]. Aliment Pharmacol Ther, 2003, 17(5): 677-682.
14. Gordon JN, Trebble TM, Ellis RD, et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial[J]. Gut, 2005, 54(4): 540-545.
15. Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity[J]. J Support Oncol, 2003, 1(3): 194-205.
16. Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation[J]. Br J Haematol, 2004, 126(5): 715-721.